CLAIMS

1. A fusion polypeptide comprising two fibronectin type III tenth (^{10}Fn3) domains,

wherein the first ^{10}Fn3 domain comprises AB, BC, CD, DE, EF, and FG loops, wherein the CD loop comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 101-125 wherein the polypeptide binds to human serum albumin with a K_D of less than 500 nM, and to one or more of rhesus serum albumin, cynomolgus serum albumin, mouse serum albumin, and rat serum albumin with a K_D of less than 500 nM; and

wherein the second ^{10}Fn3 domain binds to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9).

2. The fusion polypeptide of claim 1, wherein the CD loop of the first ^{10}Fn3 domain comprises the amino acid sequence set forth in SEQ ID NO: 106.

3. The fusion polypeptide of claim 1, wherein the CD loop of the first ^{10}Fn3 domain comprises the amino acid sequence set forth in SEQ ID NO: 113.

4. The fusion polypeptide of claim 1, wherein the first ^{10}Fn3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-48, 50-74, 76-100, 185-209 and 236-260.

5. The fusion polypeptide of claim 2, wherein the first ^{10}Fn3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 55, 81, 190 and 241.

6. The fusion polypeptide of claim 3, wherein the first ^{10}Fn3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 62, 88, 197 and 248.

7. The fusion polypeptide of any one of claims 1 to 6, wherein the second ^{10}Fn3 domain comprises the amino acid sequence set forth in SEQ ID NO: 167.

8. The fusion polypeptide of any one of claims 1-7, wherein the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 168.

9. The fusion polypeptide of any one of claims 1-7, wherein the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 169.

10. The fusion polypeptide of claim 1, wherein the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 261.

11. A composition comprising a fusion polypeptide of any one of claims 1 to 10 and a carrier.

12. An isolated nucleic acid molecule encoding the fusion polypeptide of any one of claims 1 to 10.

13. The isolated nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NOs: 127-151 and 172.

14. An expression vector comprising a nucleotide sequence encoding the fusion polypeptide of any one of claims 1 to 10.

15. A cell comprising a nucleic acid molecule of claim 12 or 13 or the expression vector of claim 14.

16. A method of producing the fusion polypeptides of any one of claims 1 to 10 comprising culturing the cell of claim 15 under conditions suitable for expressing the polypeptide, and purifying the polypeptide.

17. Use of the fusion polypeptide of any one of claims 1 to 10 or the composition of claim 11 in the manufacture of a medicament for the treatment of atherosclerosis in a subject in need thereof.

18. Use of the fusion polypeptide of any one of claims 1 to 10 or the composition of claim 11 in the manufacture of a medicament for the treatment of hypercholesterolemia in a subject in need thereof.